Alterations in blood volume and oxygen concentrations are one of the main problems in worldwide health. It is now well established that many of society's most devastating and costly neurological diseases and disorders arise from different kind of Brain Hypoxia-Ischemia (BHI). BHI is not only a trauma that occurs, in adults if not also in new-born . In some cases, deficits are seen in childhood and in others they are substantially delayed; arising in adolescence or young adulthood. Animal models of Brain hypoxia are crucial for elucidating underlying mechanisms and for development of strategies of neuroprotection and remediation. Despite of the new therapeutic strategies used mainly experimentally only hypothermia have shown some clinical benefits effects. As there is not an established treatment for Brain, neuroprotection becomes imperative. The understanding of PA pathophysiology contributes to the search for neuroprotective agents. The primary insult, characterized by a severe energetic crisis, lactate accumulation and acidosis, is exacerbated during reoxygenation period, which is associated with free radicals accumulation, oxidative stress, cell damage and inflammatory cascades. This latent phase, where secondary injury can occur, offers a therapeutic window and constitutes the basis for neuroprotection. The aim of this special issue is bringing together research addressing the role of neuroprotective agents.
The audience will mainly be experts in the field. This special issue will be very specific on its aims, focusing on neuroprotective strategies for Brain, their possible pathways and the use of pharmacological analogs. Potential topics include, but are not limited to:
* Biochemical and physiological aspects of neuroprotective agent
* Physiopathological aspects of Brain Hypoxia
* Pharmacological and genetic strategies targeting
*Beneficial effects of neuroprotective agents on , neuroplasticity and behavior.
*Clinical-related aspects of neuroprotective agents on -associated damage and recovery following PA.
* Silico Integrative Approach of neuroprotective agents.
Alterations in blood volume and oxygen concentrations are one of the main problems in worldwide health. It is now well established that many of society's most devastating and costly neurological diseases and disorders arise from different kind of Brain Hypoxia-Ischemia (BHI). BHI is not only a trauma that occurs, in adults if not also in new-born . In some cases, deficits are seen in childhood and in others they are substantially delayed; arising in adolescence or young adulthood. Animal models of Brain hypoxia are crucial for elucidating underlying mechanisms and for development of strategies of neuroprotection and remediation. Despite of the new therapeutic strategies used mainly experimentally only hypothermia have shown some clinical benefits effects. As there is not an established treatment for Brain, neuroprotection becomes imperative. The understanding of PA pathophysiology contributes to the search for neuroprotective agents. The primary insult, characterized by a severe energetic crisis, lactate accumulation and acidosis, is exacerbated during reoxygenation period, which is associated with free radicals accumulation, oxidative stress, cell damage and inflammatory cascades. This latent phase, where secondary injury can occur, offers a therapeutic window and constitutes the basis for neuroprotection. The aim of this special issue is bringing together research addressing the role of neuroprotective agents.
The audience will mainly be experts in the field. This special issue will be very specific on its aims, focusing on neuroprotective strategies for Brain, their possible pathways and the use of pharmacological analogs. Potential topics include, but are not limited to:
* Biochemical and physiological aspects of neuroprotective agent
* Physiopathological aspects of Brain Hypoxia
* Pharmacological and genetic strategies targeting
*Beneficial effects of neuroprotective agents on , neuroplasticity and behavior.
*Clinical-related aspects of neuroprotective agents on -associated damage and recovery following PA.
* Silico Integrative Approach of neuroprotective agents.
